AstraZeneca Cuts 600 US Jobs in Restructuring

AstraZeneca has eliminated about 600 U.S. commercial positions in its respiratory and immunology businesses, including roles promoting asthma treatments Breztri and Airsupra. The company says some affected employees may be reassigned. The cuts are an early step in a three-year cost-saving and restructuring plan intended to generate about $1.5 billion in annual savings and redirect resources toward drug development, including oncology and rare-disease programs.